[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561408":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":11,"centralContacts":30,"locations":39,"responsibleParty":57,"collaborators":11,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":11,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":11,"studyType":72,"phases":73,"briefSummary":76,"conditions":77,"keywords":11,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Shanghai Hengrui Pharmaceutical Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SHR-A2102 in Combination with Adebrelimab and SHR-8068","EXPERIMENTAL",null,[13,14,15],"Drug: SHR-A2102","Drug: Adebelimab (SHR-1316)","Drug: SHR-8068",[17,22,26],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":11},"DRUG","SHR-A2102","SHR-A2102: injection, 80mg\u002F bottle, intravenous drip",[9],{"type":18,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"Adebelimab (SHR-1316)","Adebelimab (SHR-1316): injection, 600mg(12mL)\u002F bottle, intravenous drip",[9],{"type":18,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"SHR-8068","SHR-8068: injection, 50mg（10mL）\u002F bottle, intravenous drip",[9],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":11,"email":35},"Xin Xu","CONTACT","0518-82342973","xin.xu@hengrui.com",{"name":37,"role":33,"phone":34,"phoneExt":11,"email":38},"Yunfei Zhang","yunfei.zhang.yz277@hengrui.com",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Shanghai Chest Hospital","RECRUITING","Shanghai","Shanghai Municipality","200030","China","CN",{"type":49,"coordinates":50},"Point",[51,52],121.45806,31.22222,{"lat":52,"lon":51},[55],{"name":56,"role":33,"phone":11,"phoneExt":11,"email":11},"Hua Zhong",{"type":58,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100561408","phase-1-a-study-of-shr-a2102-in-combination-with-adebrelimab-and-shr-8068-in-subjects-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-100561408",false,"NCT06589778","A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","Safety, Tolerability, and Efficacy of SHR-A2102 in Combination With Adebrelimab, With SHR-8068, in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase IB\u002FII Open-Label, Multicenter Clinical Study","Inclusion Criteria:\n\n1. Subjects are able to give voluntary informed consent, understand the study and are willing to follow and complete all the test procedures.\n2. Age 18\\~70 years old.\n3. Pathologically confirmed unresectable locally advanced\u002Fmetastatic non-small cell lung cancer.\n4. At least one measurable lesion per RECIST v1.1 criteria.\n5. ECOG PS score: 0-1.\n\nExclusion Criteria:\n\n1. Active or symptomatic brain metastases.\n2. Previous diagnosis of any other malignancy.\n3. Clinically symptomatic moderate to severe ascites; Uncontrollable or moderate or above pleural effusion, pericardial effusion.\n4. Received anti-tumor therapy 4 weeks prior to initiation of study treatment.\n5. Uncontrolled tumor-related pain.\n6. Subjects with severe cardiovascular and cerebrovascular diseases.","ALL","18 Years","70 Years",{"count":70,"type":71},124,"ESTIMATED","INTERVENTIONAL",[74,75],"PHASE1","PHASE2","This study is a multicenter, open-label, dose-finding\u002Fefficacy-expanding Phase IB\u002FII clinical trial to evaluate SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer. The study consists of two phases: Phase IB to explore the safety\u002Ftolerability of SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer; Phase II: To explore the efficacy of SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer.",[78],"Non-Small Cell Lung Cancer","2024-11-07",{"date":81,"type":82},"2024-11-12","ACTUAL",{"date":84,"type":82},"2024-09-27",{"date":86,"type":71},"2026-04-30",{"name":5,"class":6},1]